VIATRIS INC. Capital Expenditures
VIATRIS INC. (VTRS) reported Capital Expenditures of $92.70 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-06
- VIATRIS INC. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $52.80M, a 0.19% decline year-over-year.
- VIATRIS INC. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $39.90M, a 6.34% decline year-over-year.
- VIATRIS INC. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $196.50M, a 39.96% increase year-over-year.
- VIATRIS INC. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $86.80M, a 12.73% increase year-over-year.
- VIATRIS INC. payments to acquire property, plant, and equipment for fiscal 2025 was $378.80M, a 16.20% increase from fiscal 2024.
- VIATRIS INC. payments to acquire property, plant, and equipment for fiscal 2024 was $326.00M, a 13.53% decline from fiscal 2023.
- VIATRIS INC. payments to acquire property, plant, and equipment for fiscal 2023 was $377.00M, a 7.14% decline from fiscal 2022.
- VIATRIS INC. payments to acquire property, plant, and equipment for fiscal 2022 was $406.00M, a 11.20% decline from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $52.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $92.70M 10-Q · filed 2026-08-06 | $289.20M derived: sum of 3 quarters · filed 2026-08-06 | $376.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $39.90M 10-Q · filed 2026-05-07 | $236.40M derived: sum of 2 quarters · filed 2026-05-07 | $323.20M derived: sum of 3 quarters · filed 2026-05-07 | $376.10M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $196.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $283.30M derived: sum of 2 quarters · filed 2026-02-26 | $336.20M derived: sum of 3 quarters · filed 2026-08-06 | $378.80M 10-K · filed 2026-02-26 |
| 2025-09-30 | $86.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $139.70M derived: sum of 2 quarters · filed 2026-08-06 | $182.30M 10-Q · filed 2025-11-06 | $322.70M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $52.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $95.50M 10-Q · filed 2026-08-06 | $235.90M derived: sum of 3 quarters · filed 2026-08-06 | $312.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $42.60M 10-Q · filed 2026-05-07 | $183.00M derived: sum of 2 quarters · filed 2026-05-07 | $260.00M derived: sum of 3 quarters · filed 2026-05-07 | $318.80M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $140.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $217.40M derived: sum of 2 quarters · filed 2026-02-26 | $276.20M derived: sum of 3 quarters · filed 2026-02-26 | $326.00M 10-K · filed 2026-02-26 |
| 2024-09-30 | $77.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $135.80M derived: sum of 2 quarters · filed 2025-11-06 | $185.60M 10-Q · filed 2025-11-06 | $351.10M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $58.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $108.60M 10-Q · filed 2025-08-07 | $274.10M derived: sum of 3 quarters · filed 2026-02-26 | $370.00M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $49.80M 10-Q · filed 2025-05-08 | $215.30M derived: sum of 2 quarters · filed 2026-02-26 | $311.20M derived: sum of 3 quarters · filed 2026-02-26 | $379.00M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $165.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $261.40M derived: sum of 2 quarters · filed 2026-02-26 | $329.20M derived: sum of 3 quarters · filed 2026-02-26 | $377.00M 10-K · filed 2026-02-26 |
| 2023-09-30 | $95.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $163.70M derived: sum of 2 quarters · filed 2024-11-07 | $211.50M 10-Q · filed 2024-11-07 | $365.20M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $67.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $115.60M 10-Q · filed 2024-08-08 | $269.30M derived: sum of 3 quarters · filed 2025-02-27 | $373.20M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $47.80M 10-Q · filed 2024-05-09 | $201.50M derived: sum of 2 quarters · filed 2025-02-27 | $305.40M derived: sum of 3 quarters · filed 2025-02-27 | $389.30M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $153.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $257.60M derived: sum of 2 quarters · filed 2025-02-27 | $341.50M derived: sum of 3 quarters · filed 2025-02-27 | $406.00M 10-K · filed 2025-02-27 |
| 2022-09-30 | $103.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $187.80M derived: sum of 2 quarters · filed 2023-11-08 | $252.30M 10-Q · filed 2023-11-08 | $449.70M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $83.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $148.40M 10-Q · filed 2023-08-07 | $345.80M derived: sum of 3 quarters · filed 2024-02-28 | $466.80M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $64.50M 10-Q · filed 2023-05-08 | $261.90M derived: sum of 2 quarters · filed 2024-02-28 | $382.90M derived: sum of 3 quarters · filed 2024-02-28 | $472.20M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $197.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $318.40M derived: sum of 2 quarters · filed 2024-02-28 | $407.70M derived: sum of 3 quarters · filed 2024-02-28 | $457.20M 10-K · filed 2024-02-28 |
| 2021-09-30 | $121.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $210.30M derived: sum of 2 quarters · filed 2022-11-07 | $259.80M 10-Q · filed 2022-11-07 | $376.70M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $89.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $138.80M 10-Q · filed 2022-08-08 | $255.70M derived: sum of 3 quarters · filed 2023-02-27 | $293.90M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $49.50M 10-Q · filed 2022-05-09 | $166.40M derived: sum of 2 quarters · filed 2023-02-27 | $204.60M derived: sum of 3 quarters · filed 2023-02-27 | $249.10M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $116.90M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $155.10M derived: sum of 2 quarters · filed 2023-02-27 | $199.60M derived: sum of 3 quarters · filed 2023-02-27 | $243.00M 10-K · filed 2023-02-27 |
| 2020-09-30 | $38.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $82.70M derived: sum of 2 quarters · filed 2021-11-08 | $126.10M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $44.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $87.90M 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $43.40M 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | $213.20M 10-K · filed 2022-02-28 | |||
| 2018-12-31 | $252.10M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |